Related Experiment Video
Updated: Aug 12, 2026

Development of an Insert Co-culture System of Two Cellular Types in the Absence of Cell-Cell Contact
Published on: July 17, 2016
Cathelicidin-Related Antimicrobial Peptide Negatively Regulates Bacterial Endotoxin-Induced Glial Activation
Anup Bhusal1,2, Youngpyo Nam1, Donggun Seo1
1Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
Abstract:
Recent studies have suggested that mouse cathelicidin-related antimicrobial peptide (CRAMP) and its human homologue leucine leucine-37 (LL-37) play critical roles in innate immune responses. Here, we studied the role of mouse CRAMP in bacterial endotoxin lipopolysaccharide (LPS)-induced neuroinflammation. CRAMP peptide treatment significantly inhibited LPS-mediated inflammatory activation of glial cells in culture. In the animal model of LPS-induced neuroinflammation, CRAMP expression was highly induced in multiple cell types, such as astrocytes, microglia, and neurons. Injection of exogenous CRAMP peptide significantly inhibited inflammatory cytokine expression and the reactivity of glial cells in the mouse brain following intraperitoneal or intracerebroventricular LPS administration. Altogether, results of the study suggest that CRAMP plays an important part in containment of LPS-induced neuroinflammatory responses, and that CRAMP can be exploited for the development of targeted therapies for neuroinflammatory conditions associated with bacterial infection.
Insights
Mouse cathelicidin-related antimicrobial peptide (CRAMP) limits neuroinflammation. CRAMP peptide treatment inhibited inflammatory responses in glial cells and the mouse brain, suggesting therapeutic potential.
Area of Science:
- Neuroscience
- Immunology
- Microbiology
Background:
- Mouse cathelicidin-related antimicrobial peptide (CRAMP) and human leucine-leucine-37 (LL-37) are key in innate immunity.
- Bacterial endotoxin lipopolysaccharide (LPS) triggers neuroinflammation.
Purpose of the Study:
- Investigate CRAMP's role in LPS-induced neuroinflammation.
- Evaluate CRAMP peptide's therapeutic potential for neuroinflammatory conditions.
Main Methods:
- In vitro studies of CRAMP on LPS-stimulated glial cells.
- In vivo studies using an LPS-induced neuroinflammation mouse model.
- Assessed CRAMP expression in astrocytes, microglia, and neurons.
- Administered exogenous CRAMP via intraperitoneal and intracerebroventricular routes.
Main Results:
- CRAMP peptide inhibited LPS-induced inflammatory activation of glial cells in culture.
- CRAMP expression was upregulated in astrocytes, microglia, and neurons in LPS-treated mice.
- Exogenous CRAMP significantly reduced inflammatory cytokine expression and glial cell reactivity in the mouse brain.
- CRAMP demonstrated efficacy following both systemic and central LPS administration.
Conclusions:
- CRAMP plays a crucial role in mitigating LPS-induced neuroinflammation.
- CRAMP peptide shows promise as a therapeutic agent for bacterial infection-related neuroinflammatory disorders.
Related Concept Videos
GPCR Desensitization
GPCRs Regulate Adenylyl Cylase Activity
Two...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Regulation of Bacterial Virulence

